Pancreatic Cancer Research

ResearcherUniversity of GeorgiaActive in the last 2 years

Rajgopal Govindarajan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2958-5773; OpenAlex author ID A5080426559; NIH RePORTER profile ID 9613118. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 10)
Trials
0
Grants
4
Labs led
2
Collaborators
12
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper, 1 grant · 2013: 2 papers · 2014: 1 grant · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 1 grant · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 grant · 2024: none · 2025: none · 2026: 2 papers

Papers 11

  1. Dual targeting of DHODH and SLC29A1 overcomes metabolic resistance and enhances antitumor immune responses in PDAC. Co-author DOI 10.1158/1535-7163.mct-26-0461↗
  2. Loss of Regulator of G Protein Signaling 11 Promotes Protumorigenic Features in Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-25-0144↗
  3. EMT alterations in the solute carrier landscape uncover SLC22A10/A15 imposed vulnerabilities in pancreatic cancer. Last author DOI 10.1016/j.isci.2022.104193↗
  4. EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1. Last author DOI 10.1158/1535-7163.mct-20-0316↗
  5. miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-16-0327↗
  6. SET contributes to the epithelial-mesenchymal transition of pancreatic cancer. Last author DOI 10.18632/oncotarget.19067↗
  7. Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and… Last author DOI 10.1158/1541-7786.mcr-16-0083↗
  8. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. Last author DOI 10.1371/journal.pone.0053436↗
  9. Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle deliver… Last author DOI 10.1371/journal.pone.0071196↗
  10. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Last author DOI 10.1016/j.canlet.2012.03.007↗
  11. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Last author DOI 10.1158/0008-5472.can-10-2736↗

Grants 4

  1. Evaluation of the antitumorigenic roles of miR-122 in pancreatic cancer R03CA262490↗
  2. Epigenetic priming in pancreatic cancer chemotherapy R01CA188464↗
  3. Nucleoside Transporter-Connexin Interplay in Pancreatic Cancer Chemotherapy R15CA176528↗
  4. Epigenetic therapy with 3-deazaneplanocin A and gemcitabine for pancreatic cancer R03CA161832↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sau Wai Hung · 8 shared papers, 2011–2021 · strength 0.51
  2. Tejinder Kaur · 1 shared paper, 2026 · strength 0.36
  3. Hardik R. Mody · 5 shared papers, 2012–2017 · strength 0.31
  4. Brenna Weadick · 2 shared papers, 2021–2022 · strength 0.29
  5. Debasis Nayak · 2 shared papers, 2021–2022 · strength 0.29
  6. Mitch A. Phelps · 1 shared paper, 2026 · strength 0.26
  7. Fredrik I. Thege · 1 shared paper, 2026 · strength 0.26
  8. Shafia Rahman · 1 shared paper, 2026 · strength 0.26
  9. Wei Chen · 1 shared paper, 2021 · strength 0.13
  10. Terence Marques Williams · 1 shared paper, 2021 · strength 0.13
  11. Yangzom Doma Bhutia · 3 shared papers, 2011–2013 · strength 0.11
  12. Zobeida Cruz‐Monserrate · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.